Hofseth Biocare ASA : Annual General Meeting


The Annual General Meeting of Hofseth BioCare ASA was held yesterday, Thursday 30 May 2013. All items on the agenda were resolved in accordance with the proposals to the Annual General Meeting, except issue no 4: "Approval of the annual accounts and annual report for 2012, as well as cover of loss."

Chairman of the Board, Mr. Kjetil Olsen, were present and so was the CEO of Hofseth BioCare ASA, Jon Olav Ødegård. There were 26,664,936 shares were represented at the General Meeting, representing approximately 37.83% of the share capital.

The Annual General Meeting (AGM) hereunder did not approve the financial statements and annual report of Hofseth BioCare ASA because the annual report had not been delivered and closed, due to outstanding issues with the Auditor.

Consequent on the decision of the AGM, the Board of Directors call for an Extraordinary General Meeting on the June 21st 2013, at 1500 hours.

Kjetil Olsen was re-elected as Chairman of the Board of Directors. Hege Charlotte Bakken was elected as new board member. Roger Hofseth, Anne Kristin Holmeide and Bjørn Tunheim were all re-elected as board members. Ola Holen and Bobbi Walters were elected as "vara".

Ola Holen, Roger Hofseth and Lennart Clausen were elected to the nomination committee.

Please find enclosed the protocol from the Annual General Meeting.

For further information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Tel: +47 936 32 966
E-mail: joo@h-bc.no
 
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil
extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. HBCs objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.
 
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments

Minutes from Annual General Meeting HBC 2013
GlobeNewswire

Recommended Reading